PD-L1单抗-话题@MedSci

#PD-L1单抗#

49篇内容 | 1275人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2118070, encodeId=de8221180e05e, content=<a href='/topic/show?id=93f4128920b' target=_blank style='color:#2F92EE;'>#NMPA#</a>批准<a href='/topic/show?id=eb5d52826d4' target=_blank style='color:#2F92EE;'>#恒瑞医药#</a>抗<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a><a href='/topic/show?id=404d1054e621' target=_blank style='color:#2F92EE;'>#阿得贝利单抗#</a>一线治疗<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>（<a href='/topic/show?id=c7d61054e706' target=_blank style='color:#2F92EE;'>#EC-SCLC#</a>）上市，不过与对照组相比，提高仍然极少。从数据上看，阿得贝利单抗联合化疗一线治疗ES-SCLC的中位OS达15.3个月（vs 化疗12.8个月），2年生存率达31.3%（vs化疗 17.2%），中位无进展生存期（PFS）达5.8个月（vs化疗5.6个月），相较于化疗组显著降低患者疾病进展风险达33%。PFS几乎是一样，说明EC-SCLC进展速度很快，不过好在，一旦PFS获得一定的获益以后，OS还有一定的提升，从12.8个月上升至15.3个月，2年生存率也不错，表明免疫治疗在<a href='/topic/show?id=489a16042c4' target=_blank style='color:#2F92EE;'>#SCLC#</a>中也有<a href='/topic/show?id=8d951054e8d2' target=_blank style='color:#2F92EE;'>#长尾效应#</a>。, objectTitle=NMPA批准恒瑞医药抗PD-L1单抗阿得贝利单抗一线治疗小细胞肺癌上市, objectType=article, longId=761992, objectId=e3dfe61992f8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/dc6b84b8f7ef48689bc3b410f0446f8c.jpg, objectUrl=/article/show_article.do?id=e3dfe61992f8, replyNumber=0, likeNumber=85, createdTime=2023-03-07, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e3dfe61992f8, moduleTitle=NMPA批准恒瑞医药抗PD-L1单抗阿得贝利单抗一线治疗小细胞肺癌上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3dfe61992f8)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1538997, encodeId=1a7e153899eb4, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, objectType=article, longId=220988, objectId=1236220988e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1236220988e5, replyNumber=0, likeNumber=29, createdTime=2021-11-26, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1236220988e5, moduleTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1236220988e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538996, encodeId=a139153899624, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=27, createdTime=2020-10-31, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538995, encodeId=e2601538995d0, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, objectType=article, longId=199855, objectId=787719985534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787719985534, replyNumber=0, likeNumber=39, createdTime=2020-08-24, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787719985534, moduleTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787719985534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538994, encodeId=e19b15389945b, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=37, createdTime=2020-08-03, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538993, encodeId=379a153899369, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, objectType=article, longId=198551, objectId=2cb719855145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb719855145, replyNumber=0, likeNumber=38, createdTime=2020-08-03, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb719855145, moduleTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb719855145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538992, encodeId=ccb315389922a, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, objectType=article, longId=197602, objectId=cbf019e602e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf019e602e0, replyNumber=0, likeNumber=42, createdTime=2020-07-17, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf019e602e0, moduleTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf019e602e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538991, encodeId=ff41153899108, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=41, createdTime=2020-07-16, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538990, encodeId=255c153899098, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, objectType=article, longId=196892, objectId=c2de19689221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2de19689221, replyNumber=0, likeNumber=30, createdTime=2020-07-03, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2de19689221, moduleTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2de19689221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538989, encodeId=c2ac153898925, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, objectType=article, longId=196545, objectId=5a8619654517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8619654517, replyNumber=0, likeNumber=37, createdTime=2020-06-28, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8619654517, moduleTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a8619654517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538988, encodeId=04d0153898829, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, objectType=article, longId=196482, objectId=3e9419648230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9419648230, replyNumber=0, likeNumber=32, createdTime=2020-06-27, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9419648230, moduleTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e9419648230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538987, encodeId=31d6153898ea4, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, objectType=article, longId=196293, objectId=15011962937c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15011962937c, replyNumber=0, likeNumber=30, createdTime=2020-06-24, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15011962937c, moduleTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15011962937c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538986, encodeId=382c15389864b, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, objectType=article, longId=196192, objectId=ea03196192c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea03196192c4, replyNumber=0, likeNumber=32, createdTime=2020-06-22, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea03196192c4, moduleTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea03196192c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538985, encodeId=e2bd15389856f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, objectType=article, longId=195499, objectId=9c0719549995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0719549995, replyNumber=0, likeNumber=36, createdTime=2020-06-10, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0719549995, moduleTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0719549995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538984, encodeId=79f615389846c, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, objectType=article, longId=194614, objectId=d3b0194614fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b0194614fc, replyNumber=0, likeNumber=43, createdTime=2020-05-24, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b0194614fc, moduleTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b0194614fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538983, encodeId=c9a215389837f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗, objectType=article, longId=194430, objectId=b3b9194430bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b9194430bd, replyNumber=0, likeNumber=35, createdTime=2020-05-21, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b9194430bd, moduleTitle=美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b9194430bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538982, encodeId=b39315389820f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=35, createdTime=2020-05-19, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538981, encodeId=3e561538981bc, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), objectType=article, longId=194241, objectId=a91619424150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91619424150, replyNumber=0, likeNumber=33, createdTime=2020-05-17, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91619424150, moduleTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91619424150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538980, encodeId=45091538980c8, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, objectType=article, longId=191241, objectId=eff619124151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eff619124151, replyNumber=0, likeNumber=36, createdTime=2020-04-03, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eff619124151, moduleTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eff619124151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538979, encodeId=de9f15389e9ba, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, objectType=article, longId=189361, objectId=9e5418936139, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e5418936139, replyNumber=0, likeNumber=34, createdTime=2020-03-06, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e5418936139, moduleTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5418936139)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1单抗

2020-05-29

showtest (审核中...)

前往app查看评论内容

全文收起 #NMPA#批准#恒瑞医药#抗#PD-L1单抗##阿得贝利单抗#一线治疗#小细胞肺癌#（#EC-SCLC#）上市，不过与对照组相比，提高仍然极少。从数据上看，阿得贝利单抗联合化疗一线治疗ES-SCLC的中位OS达15.3个月（vs 化疗12.8个月），2年生存率达31.3%（vs化疗 17.2%），中位无进展生存期（PFS）达5.8个月（vs化疗5.6个月），相较于化疗组显著降低患者疾病进展风险达33%。PFS几乎是一样，说明EC-SCLC进展速度很快，不过好在，一旦PFS获得一定的获益以后，OS还有一定的提升，从12.8个月上升至15.3个月，2年生存率也不错，表明免疫治疗在#SCLC#中也有#长尾效应#。

NMPA批准恒瑞医药抗PD-L1单抗阿得贝利单抗一线治疗小细胞肺癌上市

2023-03-07发表于上海

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！

2021-11-26

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2020-10-31

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌

2020-08-24

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2020-08-03

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法

2020-08-03

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌

2020-07-17

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-07-16

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗

2020-07-03

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率

2020-06-28

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗

2020-06-27

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌

2020-06-24

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功

2020-06-22

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌

2020-06-10

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌

2020-05-24

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗

2020-05-21

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2020-05-19

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究)

2020-05-17

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗

2020-04-03

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！

2020-03-06

科室
- - 订阅+
  - 更多科室
工具
服务